Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China's iPharma in $120 Million Deal for Mologen's Immunotherapy Candidate

publication date: Dec 6, 2015

China's iPharma signed a binding term sheet to in-license Greater China rights for a clinical-stage immunotherapy candidate from Mologen (F: MGN) of Berlin. The deal could be worth up to $120 million plus royalties. iPharma is an in-licensing joint venture formed by I-Bridge Capital of China and BioLineRx (NSDQ/TASE: BLRX), an Israeli pharma. iPharma will own China rights to Mologen's lead asset, lefitolimod, which is currently in a Phase III trial for colorectal cancer and a Phase II trial for lung cancer.

Share this with colleagues:

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital